Ru­bius lands $120M bo­nan­za to fund a ground­break­ing pipeline ef­fort on a new drug plat­form

The peo­ple at Ru­bius Ther­a­peu­tics think they’re on to a game-chang­ing new plat­form for drug R&D, one that can spawn a wave of trans­for­ma­tion­al new med­i­cines. And they now have one of the biggest ven­ture cap­i­tal rounds in drug R&D this year to put their dreams to the test in a line­up of new pro­grams now head­ed for the clin­ic.

Seed­ed by Flag­ship Pi­o­neer­ing and ini­tial­ly backed with a $25 mil­lion A round in late 2015, Ru­bius to­day is un­cork­ing a $120 mil­lion in­vest­ment “to move a wave of prod­ucts in­to the clin­ic next year,” says Ru­bius Pres­i­dent Tor­ben Straight Nis­sen. Af­ter dou­bling the staff to 40 over the last 9 months, Ru­bius will now shoot for 100 over the next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.